Finance

Meta could disappoint some investors with its outlook, but long-term investors should pay attention.

The S&P 500 is trading at valuation levels last seen before the dot-com bubble, with a disconnect between new highs and new lows.

One of the largest Social Security raises of the last 35 years has a dark side.

Rocket Companies is becoming a real-estate powerhouse, and its shares seem undervalued.

Nvidia will have a monster comeback in 2027.

Space industry experts see this business growing 18% annually over the next five years. Here’s what that implies for space stock valuations.

The new massive media conglomerate has a lot to prove.

SpaceX looks poised to outperform Micron in the coming years.

It can make sense to check out what big investors are doing with their money.

VanEck’s lower 0.35% expense ratio appeals to cost-conscious investors, while First Trust’s $2.9 billion in assets and equal-weighted approach offer broader diversification across 30 biotech holdings.

At one time, Bitcoin had 1,000x upside potential. But is that still the case?

Coupang trades at a fraction of MercadoLibre’s sales multiple, but the Latin American fintech giant generates far superior margins and cash flow.

Abbott has a low-risk profile with significant upside potential.

Tilray’s stock isn’t the bargain it appears to be at first.

The two earlier streaks like it both ended with a down year of over 30%. Is today’s run built any differently?

CrowdStrike trades at a steep premium despite ongoing profitability challenges, while UiPath has just turned profitable with a valuation multiple a fraction of its rival’s.

Investors should be thinking about monetization strategies.

Shares have moved lower by 3% so far this month.

IHE concentrates 23.6% in Eli Lilly and delivers 1.4% yield, while XPH spreads risk across 62 holdings with a lower 0.35% expense ratio.

SpaceX must prove its AI spending is worth the near-term pain.